In type 2 diabetes with CKD and additional CV risk factors, sotagliflozin reduced total MACE vs. placebo at a median 14 mo.

Thakkar, Aarti; Newby, L Kristin; ACP Journal Club Editorial Team at McMaster University · Ann Intern Med · 2025

Where this comes from

Record sourced from PubMed, PMID 40456154.
Also identified by DOI 10.7326/ANNALS-25-01791-JC.
No licence information is recorded for this record.
Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.

Abstract

GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text] Endocrinology: [Formula: see text] Nephrology: [Formula: see text].

Read the full text

View on PubMed · Publisher (DOI)